ストックスクリーナーアプリを入手
4.70
11.64%
0.49
アフターアワーズ：
4.70
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch
Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
Research Analysts Set Expectations for ALDX FY2024 Earnings - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Increase in Short Interest - MarketBeat
Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat
Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan
Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha
Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
(ALDX) Trading Advice - Stock Traders Daily
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan
International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat
(ALDX) Long Term Investment Analysis - Stock Traders Daily
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR
Aldyera therapeutics director Nancy Miller-Rich buys $10,446 in stock - Investing.com
(ALDX) Investment Analysis - Stock Traders Daily
Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR
(ALDX) Proactive Strategies - Stock Traders Daily
American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine
Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada
Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan
Aldeyra Therapeutics extends loan agreement terms - Investing.com India
Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK
Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com
Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada
What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News
Aldeyra Therapeutics Inc (ALDX) rating upgrades by Oppenheimer - Knox Daily
Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex
Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Perceptive Advisors LLC Buys 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
(ALDX) Trading Signals - Stock Traders Daily
Market Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on a High Note at 5.65 - The Dwinnex
What technical indicators reveal about ALDX stock - US Post News
Bank of New York Mellon Corp Has $648,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Get in on Aldeyra Therapeutics Inc’s (ALDX) buy-in window today! - SETE News
Federated Hermes Inc. Takes Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Federated Hermes Inc. Invests $1.76 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug - RTTNews
Los Angeles Capital Management LLC Decreases Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Oppenheimer Upgrades Aldeyra Therapeutics Inc (ALDX) to an Outperform from a Perform - Knox Daily
PFG Investments LLC Purchases Shares of 396,247 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Stock Sees Surge of Approximately 20.38% in Last Five Days - Knox Daily
There is no doubt that Aldeyra Therapeutics Inc (ALDX) ticks all the boxes. - SETE News
Metric Deep Dive: Understanding Aldeyra Therapeutics Inc (ALDX) Through its Ratios - The Dwinnex
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
High Growth Tech Stocks To Watch In The United States - Simply Wall St
Aldeyra Therapeutics Inc (ALDX) requires closer examination - US Post News
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):